well said mate!
I also grabbed a few under .10 c recently. The fact we have three deals in the works that continue to progress is reassuring enough for me to continue sailing the high seas, the sp movement is always something to consider but it can often just be noise with smaller caps. The illiquid nature of bgt (for now) means any big holder can cause violent sp swings in either direction, therein lies the opportunity if you have the conviction/financial strength and are not prone to emotional stress. I guess time will tell now as we approach bigger and more significant milestones that the market will not be able to ignore, I really like the risk/reward now and feel that the risk is decreasing with each positive announcement.
Agree that the next development will likely be STK term finalization. Additionally, registration developments, new commercial agreements and potentially some non dilutive funding in the works as we may be in need of capital soon, quarterly should give a better idea of that picture.
- Forums
- ASX - By Stock
- BGT
- Ann: Bio-Gene Extends Commercial Development Agreement
Ann: Bio-Gene Extends Commercial Development Agreement, page-24
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BGT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.7¢ |
Change
-0.003(6.00%) |
Mkt cap ! $9.463M |
Open | High | Low | Value | Volume |
5.0¢ | 5.0¢ | 4.7¢ | $997 | 21.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10763 | 4.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.7¢ | 9000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10763 | 0.046 |
1 | 96000 | 0.044 |
1 | 33333 | 0.043 |
2 | 27375 | 0.040 |
1 | 120050 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.047 | 9000 | 1 |
0.050 | 83647 | 2 |
0.052 | 67000 | 1 |
0.061 | 10103 | 1 |
0.063 | 10761 | 1 |
Last trade - 15.58pm 13/11/2024 (20 minute delay) ? |
Featured News
BGT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online